Research

rs3758391 — SIRT1

Promoter-region variant in SIRT1 affecting deacetylase expression; T allele elevates SIRT1 levels and is associated with better cognition but increased metabolic and cancer risk; C allele is the common protective form

Moderate Risk Factor Share

Details

Gene
SIRT1
Chromosome
10
Risk allele
T
Clinical
Risk Factor
Evidence
Moderate

Population Frequency

CC
39%
CT
48%
TT
13%

See your personal result for SIRT1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SIRT1 Promoter Variant — Expression Tuning at the Master Longevity Switch

SIRT1 (Sirtuin 1) is often called the master regulator of aging biology. This NAD+-dependent protein deacetylase11 NAD+-dependent protein deacetylase
an enzyme that removes acetyl groups from proteins in a reaction that consumes NAD+, coupling cellular energy status to gene regulation
coordinates DNA repair, inflammation suppression, mitochondrial biogenesis, insulin sensitivity, and stress resistance across virtually every tissue. rs3758391 lies approximately 2 kb upstream of the SIRT1 transcription start site — in the promoter region that determines how much SIRT1 protein the cell makes.

The Mechanism

The T allele at rs3758391 is associated with higher SIRT1 mRNA and protein expression, while the common C allele is associated with a more moderate expression level. The AMD study by Kaikaryte et al.22 The AMD study by Kaikaryte et al.
Kaikaryte K et al. SIRT1: Genetic Variants and Serum Levels in Age-Related Macular Degeneration. Life (Basel). 2022
found that individuals carrying at least one T allele had significantly elevated serum SIRT1 levels compared with CC homozygotes. This might seem paradoxical given that SIRT1 is generally considered protective in aging — but the relationship between SIRT1 expression level and disease risk is not linear. Chronically elevated SIRT1 can disrupt normal cell-cycle checkpoints in proliferating cells, contributing to cancer susceptibility, while the same elevated SIRT1 may benefit post-mitotic tissues like neurons.

The rs3758391 promoter variant is part of a broader regulatory haplotype that includes rs3818292 (intron 1) and rs7895833 (intron 5). The G-T-G combination across these three sites modulates SIRT1 expression in a tissue- and age-specific manner.

The Evidence

Cognitive aging: The Leiden 85-plus study33 The Leiden 85-plus study
Kuningas M et al. SIRT1 gene, age-related diseases, and mortality: the Leiden 85-plus study. J Gerontol A Biol Sci Med Sci. 2007
followed 1,245 very elderly participants and found that T allele carriers showed better cognitive functioning and a trend toward lower cardiovascular mortality. A Han Chinese aging cohort44 Han Chinese aging cohort
Zhang WG et al. SIRT1 variants are associated with aging in a healthy Han Chinese population. Clin Chim Acta. 2010
of 482 individuals (246 aged 60–91 years) found the C allele OR=1.453 (p=0.026) and CC genotype OR=3.042 (p=0.027) were more prevalent in older participants, interpreted as the C allele correlating with reaching old age — suggesting C carriers have lower cumulative disease burden over decades.

Metabolic protection: A large Iranian study by Naseri et al. 202455 Naseri et al. 2024
Naseri R et al. Protective role of SIRT1 (rs3758391 T>C) polymorphism against T2DM and its complications: Influence on GPx activity. Health Sci Rep. 2024
(n=398) found the C allele protective against type 2 diabetes, diabetic neuropathy, and diabetic retinopathy. CC and TC genotypes showed significantly higher glutathione peroxidase (GPx) activity than TT carriers, suggesting the C allele promotes antioxidant capacity. A Bangladeshi case-control study with meta-analysis by Ahmed et al. 202566 Ahmed et al. 2025
Ahmed R et al. Association of SIRT1 rs3758391 Polymorphism With T2DM in Bangladeshi Population. Health Sci Rep. 2025
found TT vs CC OR=3.88 (95% CI 1.34–11.25) for T2DM, with the T allele carrying 1.67-fold higher odds (95% CI 1.07–2.60).

Cancer risk: In a Chinese cohort of 206 DLBCL lymphoma patients, Kan et al. 201877 Kan et al. 2018
Kan Y et al. SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population. Cancer Cell Int. 2018
found TT carriers had OR=3.518 (95% CI 1.68–7.39) for disease and the TT genotype was an independent poor prognostic factor (HR=1.981, p=0.006). A Greek study by Papantzimas et al. 202688 Papantzimas et al. 2026
Papantzimas I et al. Association between SIRT1 rs3758391 genetic variant and susceptibility to pancreatic and gastric cancer. Ann Gastroenterol. 2026
found TC genotype protective against pancreatic cancer (OR=0.35, p=0.004) and gastric cancer (OR=0.26, p=0.006), with C allele enriched in healthy controls (OR=0.39, p<0.001).

Survival: A large Russian cohort of 3,312 individuals by Erdman et al. 202599 Erdman et al. 2025
Erdman V et al. Genetic predictors of longevity and survival in cellular homeostasis genes. Gene. 2025
found TT genotype associated with improved survival in diabetes patients (HR=0.40, p=0.006) and multimorbidity (HR=0.48, p=0.025) — suggesting TT carriers who do develop chronic disease fare better once ill, perhaps due to elevated SIRT1-mediated stress resistance.

Contradictions in the literature reflect SIRT1's tissue- and context-specific biology. The T allele's higher SIRT1 expression may benefit neurons and stressed tissues (cognitive protection, survival under disease) while heightening cancer susceptibility through disrupted cell-cycle control. The C allele's lower expression appears to reduce metabolic disease risk and improve antioxidant tone over decades.

Practical Implications

For TT carriers, supporting SIRT1 function through upstream inputs — adequate NAD+ availability, caloric sufficiency, and polyphenol intake — remains important, while cancer screening vigilance gains additional relevance. For CC carriers, the genetic architecture already provides metabolic protection; attention to maintaining the antioxidant advantages (GPx activity) through adequate selenium and zinc intake (cofactors for GPx enzymes) reinforces what the genotype already provides.

Interactions

rs3758391 participates in the rs3818292-rs3758391-rs7895833 three-variant SIRT1 haplotype. The G-T-G combination across these sites was associated with increased odds of exudative age-related macular degeneration in the Lithuanian cohort. rs3758391 also appears in haplotype combinations associated with depression comorbidity in T2DM (PMID 39612426). The full range of SIRT1 regulatory effects requires considering all three regulatory variants together, since each modulates expression through different promoter and intronic elements. The companion SNP rs7895833 is already profiled in the GeneOps database.

Nutrient Interactions

NAD+ precursors (NMN/NR) altered_metabolism
resveratrol altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant:

CC “Common Promoter” Normal

Standard SIRT1 promoter — common protective form

You carry two copies of the common C allele at this SIRT1 promoter site. About 39% of people share this genotype (frequencies range from roughly 64% CC in Europeans to around 2% in East Asians). The CC genotype is associated with moderate SIRT1 expression and is the reference genotype in multiple SIRT1 studies. This profile is associated with lower rates of type 2 diabetes, diabetic complications, and lymphoma compared to T carriers.

CT “Intermediate Expression” Intermediate Caution

One T allele — moderately elevated SIRT1 expression

The CT genotype's intermediate SIRT1 expression level may reflect a balance between the cognitive benefits associated with higher SIRT1 activity and the metabolic protection associated with lower expression. Haplotype analyses suggest that rs3758391 interacts with neighboring SIRT1 variants rs3818292 and rs7895833 — your overall SIRT1 regulatory profile depends on all three sites together.

TT “High-Expression Variant” High Risk Warning

Two T alleles — elevated SIRT1 expression with increased metabolic and cancer risk

The TT genotype's elevated SIRT1 expression creates a pleiotropic risk profile. Higher SIRT1 activity in neurons is neuroprotective — the Leiden 85-plus study found better cognitive function in T allele carriers among the very elderly. However, in dividing cells, excessive SIRT1 can impair p53-mediated cell cycle control and DNA damage checkpoints, contributing to cancer susceptibility. In metabolic tissue, the T allele's effect on SIRT1 expression may paradoxically reduce antioxidant GPx enzyme activity (lower GPx vs CC carriers), increasing oxidative damage to beta cells and contributing to T2DM risk.

The 2025 Russian survival cohort (n=3,312) found that TT carriers who develop diabetes actually live longer than non-TT diabetics (HR=0.40) — suggesting TT's SIRT1 elevation confers a resilience advantage that only manifests once a stressor is present, not in primary prevention.